Sun Pharma launches novel therapy for Dry Eye Disease in India

26 Apr 2023 , 03:40 PM

Sun Pharmaceuticals on Tuesday has launched specialty ophthalmology therapy, CEQUA, in India for patients who have Dry Eye Disease (DED) with inflammation, a commonly occurring condition.

In company’s press statement, CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology.

Kirti Ganorkar, CEO – India Business, Sun Pharma, said in a statement that “Current treatment options for Dry Eye Disease have limitations and hence a strong unmet need exists in this space. We are excited to introduce CEQUA as a new treatment option for Dry Eye Disease in India. This is an important milestone for Sun Pharma as we bring one of our key global specialty products to India.”

The company has launched the therapy in October 2019 in US market after extensive clinical studies. The prevalence of DED is higher in India compared to global prevalence. It is projected that the prevalence of DED is likely to increase to 45% in India’s urban population by 2030.